5th Edition of International Heart Congress
June 24-26, 2027 | Hybrid Event
Implantable Cardioverter Defibrillator
An Implantable Cardioverter Defibrillator (ICD) is a sophisticated medical device designed to monitor and regulate heart rhythm in individuals at risk of life-threatening arrhythmias. Implanted beneath the skin, typically near the collarbone, the ICD continuously monitors the heart's electrical activity. In the event of a dangerous arrhythmia, the device delivers precisely timed electrical shocks to restore a normal heart rhythm. This crucial intervention can be lifesaving for individuals with conditions such as ventricular tachycardia or ventricular fibrillation. Additionally, modern ICDs often incorporate pacemaker functionality, further assisting in maintaining a steady heart rate. The ICD's capability to provide both defibrillation and pacing makes it a versatile and vital tool in the management of certain cardiac conditions, enhancing the overall quality of life for those at risk of severe arrhythmias.
John R Doty
Intermountain Medical Center, United States
Agustin Joison
Cordoba Catholic University, Argentina
Thomas J Webster
Brown University, United States
Uwe Peter Tigor
Auxilius Pharma, United States
Sergey Suchkov
N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Bijoy Krishna Banik
National Institute of Pharmaceutical Education and Research (NIPER)-Guwahati, IndiaSubmit your abstract Today
Title : Healing a broken heart: One nano beat at a time
Thomas J Webster, Brown University, United States
Title : Revolutionizing heart health through Personalized & Precision Medicine (PPM): Towards personalized cardiovascular prevention, precision cardiac care & rehabilitation via optimizing Cardiac Hospital Networks
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Antibody-proteases as unique biomarkers, potential targets and translational tools of the next step generation to be used in personalized and precision cardiology practice
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Investigation of bergapten’s pharmacological activity against doxorubicin induced cardiotoxicity: supporting evidence from cellular and animal models
Bijoy Krishna Banik, National Institute of Pharmaceutical Education and Research (NIPER)-Guwahati, India
Title : Frequency of residual risk in cardiovascular secondary prevention in patients treated at the Reina Fabiola University Clinic
Agustin Joison, Cordoba Catholic University, Argentina
Title : Antidiabetic agents – From treating diabetes to providing positive cardiovascular outcome
Syed Raza, Awali Hospital, Bahrain